GlassScriptPhysician profile
Emma I Buchanan
NPI 1588013197
$2,403.48
in general payments reported to CMS, 2019-2025
30 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $671 · 2023: $773 · 2024: $355 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Education: $55.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.47 |
| Education | $55.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.71 | 2021-2025 | |
| Corium, LLC | $307.75 | 2022-2023 | Azstarys |
| Novo Nordisk INC | $187.29 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.57 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $115.45 | 2023-2025 | Rexulti |
| Cequr Corporation | $109.69 | 2023 | Cequr Simplicity |
| Ironshore Pharmaceuticals INC. | $92.98 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $88.75 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $87.45 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $79.58 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Baxter Healthcare | $75.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $73.96 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $60.84 | 2021-2022 | |
| Globus Medical, INC. | $48.01 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.88 | 2023-2024 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $32.89 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $30.50 | 2024-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $30.50 | 2022-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $28.57 | 2022 | |
| Amgen INC. | $28.30 | 2021 | |
| Clarus Therapeutics INC. | $23.83 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.75 | 2025 | Voquezna |
| Alkermes, INC. | $19.35 | 2022 | |
| Pfizer INC. | $18.59 | 2021 | |
| Corcept Therapeutics | $18.33 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $16.12 | 2021 | |
| Hologic Sales and Service, LLC | $14.73 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
| Dexcom, INC. | $12.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.